• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2017

View Archived Issues

Promius Pharma's phase II study of intranasal sumatriptan meets primary endpoint

Read More

Biomarkers predict success of Tessa Therapeutics CTL immunotherapy in nasopharyngeal cancer

Read More

Subcutaneous Orencia available for patients 2 years of age and older

Read More

Genentech returning rights to GDC-0919 to NewLink Genetics

Read More

Cascadian Therapeutics' tucatinib receives FDA orphan drug designation

Read More

FDA grants fast track status to Aeolus Pharmaceuticals' AEOL-10150

Read More

Meiji Seika Pharma's TS-3112 shows promise against antibiotic-resistant bacteria

Read More

Valeant enters agreement to sell iNova Pharmaceuticals

Read More

2X Oncology obtains IND application for 2X-111 from 2-BBB Medicines

Read More

Upadacitinib meets all primary and secondary endpoints in phase III SELECT-NEXT study

Read More

TSRI and ShangPharma Innovation enter translational research collaboration

Read More

Chitinase inhibitor OAT-889 effective in models of airway inflammation

Read More

FDA grants orphan drug status to tavokinogene telsaplasmid in unresectable metastatic melanoma

Read More

FDA requests removal of Opana ER from the market

Read More

Inovio Pharmaceuticals initiates REVEAL phase III program for VGX-3100

Read More

Iproteos discovers novel matrix metalloproteinase-2/9 inhibitors

Read More

Merck & Co. describes new oxysterols receptor LXR-beta agonists

Read More

Sensorion announces positive phase I results for SENS-401

Read More

Vitros NephroCheck test becomes available in Europe

Read More

Lilly and KeyBioscience enter strategic collaboration

Read More

Wakunaga Pharmaceutical's WFQ-228 and WFQ-253 show promise for hospital-acquired pneumonia

Read More

Burtomab granted breakthrough therapy designation for advanced form of pediatric neuroblastoma

Read More

Kissei gains exclusive rights to develop and commercialize avacopan in Japan

Read More

Eureka Therapeutics and City of Hope enter agreement for phase I clinical testing of ET1402L1 CAR-T

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe